Amphastar Patent Win Boosts Momenta, Sandoz Antitrust Case

March 21, 2018, 9:53 PM

Amphastar Pharmaceuticals got a boost in its antitrust battle with Momenta Pharmaceuticals Inc. and Sandoz Inc. when it won a related patent infringement lawsuit brought against it by the two companies.

The victory in the infringement case over the method for testing an anticoagulant drug brings Amphastar a step closer to proving that Momenta and Sandoz engaged in anticompetitive conduct. Amphastar CEO Jack Zhang said in a March 20 statement that the company would seek a $100 million bond in the patent case and pursue further damages under a separate antitrust case that was given the green light by the ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.